DAIC

MAY 6, 2024

We are committed to protecting the future commercial value of our innovative PH-HFpEF treatment,” said Chris Giordano , President & Chief Executive Officer of Tenax Therapeutics. Getty Images milla1cf Mon, 05/06/2024 - 10:48 May 6, 2024 — Tenax Therapeutics, Inc. ,

Preserved Ejection Fraction 105

Preserved Ejection Fraction Heart Failure Pulmonary Hypertension 105

DAIC

MARCH 25, 2025

25 include Efficacy and safety of finerenone across the spectrum of kidney risk in heart failure with mildly reduced or preserved ejection fraction during the session;"Innovations and Insights in Heart Failure With Preserved Ejection Fraction: Emerging Therapies, Biomarkers and Mechanistic Studies."

Preserved Ejection Fraction 52

Preserved Ejection Fraction Heart Failure Kidney Disease Research 52

DAIC

MARCH 25, 2025

25 include Efficacy and safety of finerenone across the spectrum of kidney risk in heart failure with mildly reduced or preserved ejection fraction during the session;"Innovations and Insights in Heart Failure With Preserved Ejection Fraction: Emerging Therapies, Biomarkers and Mechanistic Studies."

Preserved Ejection Fraction 52

Preserved Ejection Fraction Heart Failure Research Academic 52

DAIC

APRIL 3, 2024

Featured topics will include in-depth sessions covering non-statin lipid lowering therapies, heart failure with preserved ejection fraction, viability, imaging modalities for the assessment of coronary artery disease, and antiplatelet therapy after coronary stenting. 24 news here.

Education 105

Education Preserved Ejection Fraction Coronary Artery Disease Cardio Oncology 105

Dr. S. Venkatesan MD

APRIL 18, 2024

It is prudent to understand, that even in systolic LV failure; it is the raised LVEDP that causes the symptoms and marks the limits of exercise capacity. May be, it will come soon in the innovative lanes of cardiology. Curious minds might ask, can’t we decompress LV it self by creating a small VSD. Interview with Sanjiv J.

Preserved Ejection Fraction 40

Preserved Ejection Fraction Pulmonary Congenital Heart Disease VSD 40

DAIC

FEBRUARY 29, 2024

ET Murphy Ballroom 4 Comparison of an "Inclisiran First" Strategy with Usual Care in Patients With Atherosclerotic Cardiovascular Disease: Results From the VICTORION-INITIATE Randomized Trial Targeting Weight Loss to Personalize the Prevention of Type 2 Diabetes Once-weekly Semaglutide in Patients with Heart Failure With Preserved Ejection Fraction, (..)

Aortic valve 103

Aortic valve Myocardial Infarction Aortic Blood Pressure 103